PT  - JOURNAL ARTICLE
AU  - Bermejo-Martin, Jesús F
AU  - González-Rivera, Milagros
AU  - Almansa, Raquel
AU  - Micheloud, Dariela
AU  - Tedim, Ana P.
AU  - Domínguez-Gil, Marta
AU  - Resino, Salvador
AU  - Martín-Fernández, Marta
AU  - Murua, Pablo Ryan
AU  - Pérez-García, Felipe
AU  - Tamayo, Luis
AU  - Lopez-Izquierdo, Raúl
AU  - Bustamante, Elena
AU  - Aldecoa, César
AU  - Gómez, José Manuel
AU  - Rico-Feijoo, Jesús
AU  - Orduña, Antonio
AU  - Méndez, Raúl
AU  - Fernández Natal, Isabel
AU  - Megías, Gregoria
AU  - González-Estecha, Montserrat
AU  - Carriedo, Demetrio
AU  - Doncel, Cristina
AU  - Jorge, Noelia
AU  - Ortega, Alicia
AU  - de la Fuente, Amanda
AU  - del Campo, Félix
AU  - Fernández-Ratero, José Antonio
AU  - Trapiello, Wysali
AU  - González-Jiménez, Paula
AU  - Ruiz, Guadalupe
AU  - Kelvin, Alyson A.
AU  - Ostadgavahi, Ali Toloue
AU  - Oneizat, Ruth
AU  - María Ruiz, Luz
AU  - Miguéns, Iria
AU  - Gargallo, Esther
AU  - Muñoz, Ioana
AU  - Pelegrin, Sara
AU  - Martín, Silvia
AU  - García Olivares, Pablo
AU  - Cedeño, Jamil Antonio
AU  - Albi, Tomás Ruiz
AU  - Puertas, Carolina
AU  - Ángel Berezo, Jose
AU  - Renedo, Gloria
AU  - Herrán, Rubén
AU  - Bustamante-Munguira, Juan
AU  - Enríquez, Pedro
AU  - Cicuendez, Ramón
AU  - Blanco, Jesús
AU  - Abadia, Jesica
AU  - Barquero, Julia Gómez
AU  - Mamolar, Nuria
AU  - Blanca-López, Natalia
AU  - Valdivia, Luis Jorge
AU  - Caso, Belén Fernández
AU  - Mantecón, María Ángeles
AU  - Motos, Anna
AU  - Fernandez-Barat, Laia
AU  - Ferrer, Ricard
AU  - Barbé, Ferrán
AU  - Torres, Antoni
AU  - Menéndez, Rosario
AU  - Eiros, José María
AU  - Kelvin, David J
TI  - Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19
AID  - 10.1101/2020.08.25.20154252
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.25.20154252
4099  - http://medrxiv.org/content/early/2020/10/27/2020.08.25.20154252.short
4100  - http://medrxiv.org/content/early/2020/10/27/2020.08.25.20154252.full
AB  - Background COVID-19 can course with respiratory and extrapulmonary disease. SARS-CoV-2 RNA is detected in respiratory samples but also in blood, stool and urine. Severe COVID-19 is characterised by a dysregulated host response to this virus. We studied whether viral RNAemia or viral RNA load in plasma are associated to severe COVID-19 and also to this dysregulated response.Methods 250 patients with COVID-19 were recruited (50 outpatients, 100 hospitalised ward patients, and 100 critically ill). Viral RNA detection and quantification in plasma was performed using droplet digital PCR, targeting the N1 and N2 regions of the SARS-CoV-2 nucleoprotein gene. The association between SARS-CoV-2 RNAemia and viral RNA load in plasma with severity was evaluated by multivariate logistic regression. Correlations between viral RNA load and biomarkers evidencing dysregulation of host response were evaluated by calculating the Spearman correlation coefficients.Results the frequency of viral RNAemia was higher in the critically ill patients (78%) compared to ward patients (27%) and outpatients (2%) (p<0.001). Critical patients had higher viral RNA loads in plasma than non-critically ill patients, with non survivors showing the highest values. When outpatients and ward patients were compared, viral RNAemia did not show significant associations in the multivariate analysis. In contrast, when ward patients were compared with ICU patients, both viral RNAemia and viral RNA load in plasma were associated with critical illness (OR [CI 95%], p): RNAemia (3.92 [1.183 - 12.968], 0.025), viral RNA load (N1) (1.962 [1.244 - 3.096], 0.004); viral RNA load (N2) (2.229 [1.382 - 3.595], 0.001). Viral RNA load in plasma correlated with higher levels of chemokines (CXCL10, CCL2), biomarkers indicative of a systemic inflammatory response (IL-6, CRP, Ferritin), activation of NK cells (IL-15), endothelial dysfunction (VCAM-1, angiopoietin-2, ICAM-1), coagulation activation (D-Dimer and INR), tissue damage (LDH, GPT), neutrophil response (neutrophils counts, myeloperoxidase, GM-CSF) and immunodepression (PD-L1, IL-10, lymphopenia and monocytopenia).Conclusions SARS-CoV-2 RNAemia and viral RNA load in plasma are associated to critical illness in COVID-19. Viral RNA load in plasma correlates with key signatures of dysregulated host responses, suggesting a major role of uncontrolled viral replication in the pathogenesis of this disease.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04457505Funding StatementThis work was supported by awards from the Canadian Institutes of Health Research, the Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding initiative (CIHR OV2 170357), Research Nova Scotia (DJK), Atlantic Genome/Genome Canada (DJK), Li-Ka Shing Foundation (DJK), Dalhousie Medical Research Foundation (DJK), the Subvenciones de concesion directa para proyectos y programas de investigacion del virus SARS-CoV2, causante del COVID-19, FONDO - COVID19, Instituto de Salud Carlos III (COV20/00110, CIBERES, 06/06/0028), (AT) and finally by the Convocatoria extraordinaria y urgente de la Gerencia Regional de Salud de Castilla y Leon, para la financiacion de proyectos de investigacion en enfermedad COVID-19 (GRS COVID 53/A/20) (CA). DJK is a recipient of the Canada Research Chair in Translational Vaccinology and Inflammation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comite de Etica de la Investigacion con Medicamentos del Area de Salud de Salamanca, code PI 2020 03 452All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable requestSARS-CoV-2Severe acute Respiratory Syndrom-Coronavirus-2LDHLactate dehydrogenaseSFGranulocyte colony-stimulating factorTLRtoll like receptor